Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
985.02
+4.45 (+0.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
2 Biotech Stocks to Buy in May
May 25, 2024
You could buy these in any month, really.
Via
The Motley Fool
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
May 24, 2024
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.
Via
Benzinga
Topics
Data Breach
Exposures
Information Security
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
May 23, 2024
It might not be too late to invest in these impressive growth stocks.
Via
The Motley Fool
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
May 20, 2024
Via
Benzinga
Large Cap Biopharmaceuticals Performance
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
May 17, 2024
Via
Benzinga
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
May 03, 2024
Via
Benzinga
Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry
May 02, 2024
Via
Benzinga
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.
Via
InvestorPlace
These 2 No-Brainer Growth Stocks Are Breaking New Ground
May 16, 2024
The future keeps getting brighter for these companies.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
May 14, 2024
Via
Benzinga
Week Of May 13, 2024: What's In Store For The Markets
May 13, 2024
Timeless Wisdom and timely ideas including general market commentary along with stocks to watch.
Via
Talk Markets
Healthcare And Biotech Investing 101: What You Need To Know.
May 13, 2024
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Regeneron Earnings Miss; Biotech Giant's Stock Falls
May 02, 2024
The biotech giant's earnings and sales both missed Q1 estimates.
Via
Investor's Business Daily
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
April 30, 2024
Via
Benzinga
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
April 18, 2024
Via
Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
April 17, 2024
Via
Benzinga
Sell In May? No Way!
May 11, 2024
Many investors and members of the financial media have been asking if it would be prudent to heed the old Wall Street adage to “sell in May and go away.
Via
Talk Markets
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
May 04, 2024
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.
Via
InvestorPlace
Exposures
Product Safety
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
May 03, 2024
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
May 03, 2024
Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains.
Via
InvestorPlace
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
May 02, 2024
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.
Via
Benzinga
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
May 02, 2024
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
May 02, 2024
REGN stock results show that Regeneron Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
May 02, 2024
Via
Benzinga
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 02, 2024
It pays to develop novel medicines for life-threatening illnesses.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
April 30, 2024
Via
Benzinga
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
April 25, 2024
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.
Via
Benzinga
2 Small-Cap Growth Stocks With Room To Run
April 24, 2024
These two small-cap growth stocks could be ready to run.
Via
The Motley Fool
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.